AAPG
HEALTHCAREAscentage Pharma Group International
$21.57-0.33 (-1.51%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving AAPG Today?
No stock-specific AI insight has been generated for AAPG yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$19.11$48.45
$21.57
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-2.04
Dividend Yield—
Dividend / Share—
ROE-1.5%
Profit Margin-2.2%
Debt / Equity—
Trading
Volume5K
Avg Volume (10D)—
Shares Outstanding93.3M
AAPG News
20 articles- Global Growth Companies With High Insider Ownership In April 2026Yahoo Finance·Apr 22, 2026
- Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026GlobeNewswire Inc.·Apr 22, 2026
- Global Growth Companies With High Insider OwnershipYahoo Finance·Apr 20, 2026
- Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual MeetingYahoo Finance·Apr 20, 2026
- Global Insights Into 3 Growth Stocks With High Insider OwnershipYahoo Finance·Apr 17, 2026
- Ascentage Pharma Builds Momentum With 2 'Potential Blockbuster' Drugs, Oppenheimer SaysYahoo Finance·Mar 27, 2026
- Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business UpdatesGlobeNewswire Inc.·Mar 25, 2026
- Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026Yahoo Finance·Mar 18, 2026
- Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026Yahoo Finance·Mar 11, 2026
- A Look At Ascentage Pharma Group International’s Valuation After Recent Share Price MovesYahoo Finance·Mar 9, 2026
- Ascentage Pharma to Participate in Three Upcoming Investor ConferencesYahoo Finance·Feb 23, 2026
- BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsightYahoo Finance·Feb 12, 2026
- Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 TargetYahoo Finance·Feb 11, 2026
- Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026Yahoo Finance·Feb 9, 2026
- Ascentage Pharma Receives Clearance from China’s CDE for New DrugYahoo Finance·Feb 6, 2026
- Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288Yahoo Finance·Feb 5, 2026
- Is Ascentage Pharma Group (SEHK:6855) Price Swings Creating A Valuation Opportunity NowYahoo Finance·Jan 15, 2026
- Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 15, 2026
- Ascentage Pharma B-Cell Cancer Candidate Receives FDA IND ClearanceYahoo Finance·Jan 7, 2026
- Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288Yahoo Finance·Jan 7, 2026
All 20 articles loaded
Price Data
Open$0.00
Previous Close$21.90
Day High$0.00
Day Low$0.00
52 Week High$48.45
52 Week Low$19.11
52-Week Range
$19.11$48.45
$21.57
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-2.04
Dividend Yield—
Dividend / Share—
ROE-1.5%
Profit Margin-2.2%
Debt / Equity—
Trading
Volume5K
Avg Volume (10D)—
Shares Outstanding93.3M
About Ascentage Pharma Group International
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—